Direct compression and wet granulation lines processing Qinlian Injection Veterinary Grade API in veterinary tablet manufacture are constrained by the particle size span, bulk density, and moisture content of the incoming active. The loading ratio is set by the finished label strength rather than by a fixed API property: a 25 mg active tablet with total core mass 300 mg corresponds to 8.3% w/w API, whereas high-dose veterinary tablets may reach 35%–45% w/w active before binder and disintegrant adjustments are exhausted. Compression blends are released against Ph. Eur. 2.9.1 disintegration, Ph. Eur. 2.9.3 dissolution, and USP <711> Apparatus 2 at 50 rpm in 900 mL of pH 6.8 phosphate buffer, depending on the species-specific monograph. The downstream route typically begins with dry screening through a 0.5–0.8 mm conical mill to delump, followed by high-shear wet granulation in a vertical granulator with impeller tip speed 4–8 m/s and chopper speed 1,500–3,000 rpm; purified water or a 5%–10% w/w povidone solution is sprayed until endpoint granule size 150–400 µm is achieved. Drying in a fluid-bed dryer at inlet air 55°C–65°C is stopped at loss-on-drying 1.5%–2.5% w/w, because over-dried granulations increase friability and capping on the rotary press. Lubrication with magnesium stearate at 0.5%–1.0% w/w for 3–5 min is kept short to avoid excessive tensile strength reduction. Tablets are compressed on a rotary tablet press with compression force 8–18 kN, target hardness 6–12 kp, and friability below 1.0% w/w per USP <1216>. Film coating, where applied, is performed in a perforated pan with aqueous hydroxypropyl methylcellulose dispersion and weight gain 2.0%–3.5% w/w to mask taste and improve swallowability in companion animals. Terminal product types include uncoated tablets for oral administration to sheep and cattle, scored tablets for weight-banded dosing, flavored chewable tablets for dogs, and film-coated tablets for cats or horses. The injection-grade status of the API does not exempt tablet batches from non-sterile microbial quality release testing required by Ph. Eur. 5.1.4; endotoxin controls are determined by the finished product monograph and are normally lower than injectable limits.

What Shifts When the Injection-Grade API Is Processed into Parenteral Solutions?

Parenteral manufacturing with Qinlian Injection Veterinary Grade API shifts the primary control surface from solid-state properties to bioburden, endotoxin, and thermal stability in aqueous solution. The active is typically expressed as a concentration rather than a mass fraction; a 50 mg/mL aqueous injection corresponds to roughly 5.0% w/v before density correction, while companion-animal injectables may be formulated at 10 mg/mL to 100 mg/mL depending on solubility and viscosity. The maximum concentration is limited by the pH-solubility profile, osmolality constraints, and the risk of precipitation during temperature cycling. Release and process controls cite Ph. Eur. 2.6.1 sterility, Ph. Eur. 2.6.14 bacterial endotoxins, USP <85> endotoxin testing, 21 CFR 211.113(a) for microbiological contamination, 21 CFR 211.94(b) for container closure systems, and EU GMP Annex 1 for aseptic operations. The downstream process starts in a 316L jacketed dissolution vessel under nitrogen overlay; the API is added to water for injection at 15°C–25°C with bottom-mounted propeller agitation at 150–300 rpm. If pH adjustment is necessary, 1 N hydrochloric acid or sodium hydroxide is metered to within ±0.1 pH units of the target. The solution is prefiltered through 0.45 µm then sterilized through a 0.22 µm polyvinylidene fluoride or polyethersulfone filter, followed by filling into depyrogenated Type I glass vials that have been exposed to dry heat at 250°C for not less than 30 min. If thermal stability data support it, terminal sterilization at 121°C for 15 min is preferred over aseptic filtration because it reduces the sterility-assurance burden; heat-labile formulations proceed through aseptic filling in a Grade A zone with EU GMP Annex 1 unidirectional airflow and settle plates. Lyophilized presentations are produced when aqueous hydrolysis exceeds a stability threshold, with freezing to −40°C and primary drying shelf temperatures from −20°C to +20°C under vacuum. Terminal product types include sterile aqueous injection solutions for cattle, subcutaneous suspension products with particle size below 30 µm to avoid needle blockage, and lyophilized cakes for reconstitution with water for injection at the farm. Thermal sterilization is excluded when forced degradation data show assay loss above 5% at 121°C for 15 min; published data for this specific API configuration is limited beyond the manufacturer’s stability certificate.

In capsule filling operations, Qinlian Injection Veterinary Grade API introduces different failure modes from tablets: powder bridging, tamping-pin stickiness, and poor plug ejection. The fill mass and API mass fraction are directly tied to the dose: a 50 mg active capsule in size 2 with total fill mass 250 mg yields 20% w/w API, and veterinary capsule products commonly operate between 5% and 60% w/w active depending on whether the dose is low and diluents dominate or high and the active itself forms the bulk of the plug. Excipients include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate; the latter is maintained below 1.0% w/w to avoid dissolution slowdown. Compliance testing follows Ph. Eur. 2.9.1 disintegration, USP <711> dissolution, Ph. Eur. 2.9.40 uniformity of dosage units, and 21 CFR 211.110 for in-process blend uniformity. The downstream process begins with low-shear blending in a V-blender or bin blender for 15–20 min after the API is pre-screened through a 0.5 mm mesh. If the API batch has a Carr index above 25 or bulk density below 0.35 g/cm³, dry granulation by slugging or roller compaction is used to increase particle size and flow. Encapsulation is conducted on a tamping-pin or auger dosator machine with fill weight tolerance ±5% of target and weight uniformity checked per USP <905>. Empty capsule shells are conditioned at 35%–55% relative humidity to avoid brittleness or stickiness. Terminal product types include hard gelatin capsules for dogs and cats, HPMC capsules for vegetable-derived dry powder applications, and multiparticulate capsules containing coated granules for delayed-release or rumen-bypass delivery in ruminant species. For moisture-sensitive APIs, the capsule fill may include a desiccant sachet in the packaging rather than alteration of the capsule formulation itself.

Powder and Granule Lines Where Sieve Fraction Controls Dose Uniformity

Oral powder and granule manufacture from Qinlian Injection Veterinary Grade API places more weight on particle-size distribution and bulk density than on compression behavior, because the animal receives the product by direct top-dressing or dilution into drinking water. The active is diluted on water-soluble carriers such as lactose monohydrate, glucose, or sucrose at 10%–50% w/w for oral water-soluble powders; a sachet containing 100 g of a 20% w/w formulation delivers 20 g active, and when dosed at 1 g/L in drinking water the resulting active concentration is 200 mg/L. Granules for feed top-dressing are typically formulated at 2%–20% w/w active with starch or maltodextrin binders. Compliance requirements include Ph. Eur. 2.9.38 particle-size distribution by analytical sieving, USP <786> for sieve analysis, USP <795> for oral powders, and 21 CFR 211.110 for blend uniformity. The downstream process uses either direct blending in a double-cone or ribbon blender for soluble powders, or fluid-bed top-spray granulation for low-dust granules. Granulation is performed with inlet air 55°C–65°C, spray rate 10–30 g/min per kg of bed, and atomization air pressure 2.0–3.0 bar; drying continues until granule moisture is ≤2.0% w/w. The dried granulation is sieved to collect the 150–600 µm fraction with fines below 15% w/w, as excess fines cause segregation in sachet filling and poor flow during farm dosing. Terminal product types include water-soluble powder sachets for poultry and swine drinking water, oral suspension powders for reconstitution at the veterinary practice, and direct top-dress granules for cattle feed. Batch-to-batch variance in particle size is controlled by sieve stacking after drying, not by increasing binder content alone; over-granulation at binder levels above 5% w/w can delay dissolution in cold drinking water.

Because medicated premix production from Qinlian Injection Veterinary Grade API is deliberately low-concentration and high-dilution, the unit operation is designed to disappear into a feed mill’s total ration at consistent carryover levels. Premix formulations are commonly built at 1.0%–10.0% w/w active on a carrier such as ground corn cob, wheat middlings, or calcium carbonate; a 5% w/w premix used at 2 kg per tonne final feed delivers 100 ppm active in the finished ration. Regulatory anchors include Regulation (EC) No 183/2005 for feed hygiene with HACCP-based process control, Directive 2002/32/EC for undesirable substances, 21 CFR 225.65 sanitation and cleanout, and 21 CFR 225.42 mixing equipment requirements. The downstream process depends on geometric dilution: the API is first blended with an equal weight of carrier in a small drum blender for 5 min, then that pre-blend is expanded stepwise into the main batch. The main mixing is performed in a horizontal ribbon blender with fill level 40%–70% of working volume and mixing time 10–20 min; active content coefficient of variation should remain at or below 5% when sampled according to ISO 6497. Liquid binding agents such as soybean oil or mineral oil at 0.5%–2.0% w/w are added after the active is uniformly distributed to reduce dust and segregation. Terminal product types include medicated feed premix for swine, poultry, and ruminant feed mills, intermediate premix for on-farm mixing, and milk-replacer premix for calves. Carryover after batch discharge is controlled by ribbon blender blade clearance and vacuum cleanout because residual active in transfer lines is the dominant source of cross-contamination in multiproduct feed mills.

When a Veterinary Oral Solution Requires pH-Dependent Solubility Management

Oral solution formulation of Qinlian Injection Veterinary Grade API is governed by the pH-solubility curve, because the active must remain in solution across storage temperatures from 5°C to 40°C and after dilution in farm water. The active is usually present at 10–100 mg/mL, or 1.0%–10.0% w/v, depending on the species dose and syrup viscosity. If the API is a weak acid or weak base, pH adjustment with citrate or phosphate buffer to 4.0–6.0 is common, but the selected pH must keep the active above its equilibrium solubility by a meaningful margin; a solubility change of 0.5 log units per pH unit is typical for ionizable veterinary actives. The formulation is released against Ph. Eur. 5.1.3 efficacy of antimicrobial preservation, USP <795> nonsterile compounding for clarifications, and 21 CFR 211.67 equipment cleaning for multiproduct liquid lines. The downstream process uses a 316L jacketed mixing tank with bottom-mounted propeller agitation at 150–300 rpm; the vehicle is prepared first, pH-adjusted, then the API is added and mixed until fully dissolved. Co-solvents such as propylene glycol or glycerol are typically included at 10%–30% v/v to increase solubility and reduce microbial water activity, but levels above 30% v/v can cause excessive viscosity and poor pourability from high-density polyethylene bottles. The finished solution is filtered through a 5–10 µm polypropylene cartridge before filling into high-density polyethylene or PET bottles with tamper-evident closures. Terminal product types include oral drench solutions for cattle, calibrated pump-dose fluids for swine, and drinking-water concentrates that are diluted at 0.5–1.0 L per 1,000 L of drinking water. For thermolabile actives that degrade by hydrolysis, pH selection is often the only available stabilizer; antioxidant addition is not automatically applied unless forced degradation shows oxidative loss above 5% under accelerated conditions.